DK2013236T3 - Antistoffer, der binder til det ekstracellulære domæne af receptortyrosinkinasen alk - Google Patents

Antistoffer, der binder til det ekstracellulære domæne af receptortyrosinkinasen alk Download PDF

Info

Publication number
DK2013236T3
DK2013236T3 DK07720099.6T DK07720099T DK2013236T3 DK 2013236 T3 DK2013236 T3 DK 2013236T3 DK 07720099 T DK07720099 T DK 07720099T DK 2013236 T3 DK2013236 T3 DK 2013236T3
Authority
DK
Denmark
Prior art keywords
alk
gly
ser
ala
antibody
Prior art date
Application number
DK07720099.6T
Other languages
English (en)
Inventor
Der Maur Adrian Auf
Peter Lichtlen
Alcide Barberis
Original Assignee
Delenex Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics Ag filed Critical Delenex Therapeutics Ag
Application granted granted Critical
Publication of DK2013236T3 publication Critical patent/DK2013236T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (9)

1. scFv-antistof, der binder det humane anaplastisk lymfomkinase (ALK)-protein, hvilket scFv-antistof omfatter (i) en variabel tung kæde-sekvens ifølge SEQ.ID. No. 4 og (ii) en variabel let kæde-sekvens ifølge SEQ.ID. No. 5, hvilket antistof binder et 16 aminosyrer langt ALK-epitoppeptid ifølge SEQ. ID. No. 1 med en affinitet, Kd, på 10 nM eller derunder, og hvor antistoffet ikke binder det murine ALK-protein. 2. scFv-antistof ifølge krav 1, hvilket antistof omfatter strukturen NH2-VL-linker-VH-COOH eller NH2-VH-linker-VL-COOH, hvor linkeren har sekvensen SEQ.ID. No. 16. 3. scFv-antistof ifølge et hvilket som helst af de foregående krav, idet antistoffet mærkes radioaktivt eller mærkes med toksin. 4. scFv-antistof ifølge et hvilket som helst af de foregående krav til anvendelse som medikament eller diagnostisk værktøj.
5. Anvendelse af scFv-antistof ifølge et hvilket som helst af de foregående krav til fremstilling af et medikament til behandling af cancere eller tumorer.
6. Anvendelse ifølge krav 5, hvor medikamentet er egnet til inhibering af MK- og/eller PTN-binding til ALK og/eller ALK-medieret signalering.
7. Anvendelse ifølge krav 5 eller 6, hvor medikamentet er egnet til administration af scFv-antistoffet i kombination med et middel mod cancer, f.eks. methotrexat.
8. Anvendelse ifølge krav 5, hvor behandlingen er en behandling af neuroblastom, glioblastom, rhabdomyosarkom, brystkarcinom, melanom, pankreascancer, B-celle-NHL, skjoldbruskkirtelkarcinom, småcellet lungekarcinom, retinoblastom, Ewings sarkom, prostatacancer, tyktarmscancer, pankreascancer, lipom, liposarkom, fibrosarkom, især glioblastom, neuroblastom og rhabdomyosarkom.
9. DNA-sekvens, der koder for scFv-antistoffet ifølge et hvilket som helst af kravene 1 eller 2.
10. Ekspressionsvektor, der omfatter DNA-sekvensen ifølge krav 9.
11. Egnet værtscelle, der er transformeret med ekspressionsvektoren ifølge krav 10, især en E. coli-celle.
12. Fremgangsmåde til fremstilling af et scFv-antistof ifølge et hvilket som helst af kravene 1 eller 2, hvilken fremgangsmåde omfatter dyrkning af værtscellen ifølge krav 11 under betingelser, som muliggør syntese af scFv-antistoffet og isolering deraf fra kulturen.
DK07720099.6T 2006-04-28 2007-04-27 Antistoffer, der binder til det ekstracellulære domæne af receptortyrosinkinasen alk DK2013236T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Publications (1)

Publication Number Publication Date
DK2013236T3 true DK2013236T3 (da) 2015-09-21

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07720099.6T DK2013236T3 (da) 2006-04-28 2007-04-27 Antistoffer, der binder til det ekstracellulære domæne af receptortyrosinkinasen alk

Country Status (16)

Country Link
US (3) US7902340B2 (da)
EP (2) EP2013236B1 (da)
JP (2) JP5431920B2 (da)
KR (1) KR101457228B1 (da)
CN (1) CN101443361B (da)
AU (1) AU2007246144B2 (da)
BR (1) BRPI0710971A2 (da)
CA (1) CA2650822C (da)
DK (1) DK2013236T3 (da)
ES (1) ES2547248T3 (da)
IL (1) IL194752A0 (da)
MX (1) MX2008013705A (da)
NZ (1) NZ572248A (da)
PL (1) PL2013236T3 (da)
RU (1) RU2460540C2 (da)
WO (1) WO2007124610A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2013236T3 (pl) * 2006-04-28 2015-12-31 Delenex Therapeutics Ag Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
WO2015184231A2 (en) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
MX2018004515A (es) * 2015-10-13 2019-04-15 Eureka Therapeutics Inc Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
WO2017070608A1 (en) 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
WO2019157342A1 (en) * 2018-02-09 2019-08-15 Acceleron Pharma Inc. Methods for treating heterotopic ossification
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
EP1242457B1 (en) * 1999-12-28 2004-08-11 Esbatech AG Intrabodies with defined framework that is stable in a reducing environment and applications thereof
AU2001266876B2 (en) 2000-06-14 2006-08-31 Georgetown University Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
EP2332989B1 (en) * 2002-05-22 2015-04-01 ESBATech, an Alcon Biomedical Research Unit LLC Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
EP1789552A2 (en) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
PL2013236T3 (pl) * 2006-04-28 2015-12-31 Delenex Therapeutics Ag Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK

Also Published As

Publication number Publication date
NZ572248A (en) 2011-08-26
ES2547248T3 (es) 2015-10-02
IL194752A0 (en) 2011-08-01
CN101443361B (zh) 2015-08-19
BRPI0710971A2 (pt) 2011-05-31
JP2013226144A (ja) 2013-11-07
RU2460540C2 (ru) 2012-09-10
EP2013236B1 (en) 2015-06-17
US20080118512A1 (en) 2008-05-22
CN101443361A (zh) 2009-05-27
RU2008146922A (ru) 2010-06-10
WO2007124610A1 (en) 2007-11-08
US9512411B2 (en) 2016-12-06
US20150203829A1 (en) 2015-07-23
AU2007246144A1 (en) 2007-11-08
HK1124619A1 (en) 2009-07-17
JP2009535021A (ja) 2009-10-01
US7902340B2 (en) 2011-03-08
JP5911821B2 (ja) 2016-04-27
JP5431920B2 (ja) 2014-03-05
US20110159008A1 (en) 2011-06-30
KR101457228B1 (ko) 2014-11-04
EP2604627A1 (en) 2013-06-19
KR20080113261A (ko) 2008-12-29
MX2008013705A (es) 2008-11-06
CA2650822C (en) 2017-03-14
AU2007246144B2 (en) 2012-12-06
EP2013236A1 (en) 2009-01-14
PL2013236T3 (pl) 2015-12-31
CA2650822A1 (en) 2007-11-08
US8945563B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
DK2013236T3 (da) Antistoffer, der binder til det ekstracellulære domæne af receptortyrosinkinasen alk
CN109265550B (zh) Bcma抗体、嵌合抗原受体和药物
KR102427334B1 (ko) 키메라 항원 및 t 세포 수용체 및 사용 방법
CN109414455B (zh) Bcma结合分子及其使用方法
CN109293772B (zh) 靶向bcma蛋白的抗体、嵌合抗原受体和药物
CN112500480B (zh) 针对新型冠状病毒的纳米抗体及其应用
KR20210094509A (ko) 재조합 점액종 바이러스 및 이의 용도
KR20140093922A (ko) Ａｇｒ２ 차단 항체 및 그의 용도
KR20050119120A (ko) 인간 ⅰｌ-21 수용체에 대한 항체 및 그것의 용도
HUE027358T2 (en) Anti-mesothelin antibodies and their applications
CN111825766B (zh) 抗il-4r单域抗体及其应用
WO2008131575A2 (en) Anti-alk antibodies suitable for treating metastatic cancers or tumors
CN112245578B (zh) 一种covid-19病毒预防性疫苗及其制备方法
AU2012244351B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
CN112538117B (zh) 抗人癌胚抗原抗体及其编码基因和应用
HK1124619B (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
HK40048030A (en) Recombinant myxoma viruses and uses thereof
Marshall Towards cancer immunotherapy: Analysis of a tumor targeting antibody and engineering of a novel fusion protein to activate cytotoxic T cells